Trichostatin A enhances estrogen receptor-alpha repression in MCF-7 breast cancer cells under hypoxia.

Biochemical and Biophysical Research Communications
Hyunggyun NohYoungJoo Lee

Abstract

Estrogen receptor (ER) is a crucial determinant of resistance to endocrine therapy, which may change during the progression of breast cancer. We previously showed that hypoxia induces ESR1 gene repression and ERα protein degradation via proteasome-mediated pathway in breast cancer cells. HDAC plays important roles in the regulation of histone and non-histone protein post-translational modification. HDAC inhibitors can induce epigenetic changes and have therapeutic potential for targeting various cancers. Trichostatin A exerts potent antitumor activities against breast cancer cells in vitro and in vivo. In this report, we show that TSA augments ESR1 gene repression at the transcriptional level and downregulates ERα protein expression under hypoxic conditions through a proteasome-mediated pathway. TSA-induced estrogen response element-driven reporter activity in the absence of estrogen was synergistically enhanced under hypoxia; however, TSA inhibited cell proliferation under both normoxia and hypoxia. Our data show that the hypoxia-induced repression of ESR1 and degradation of ERα are enhanced by concomitant treatment with TSA. These findings expand our understanding of hormone responsiveness in the tumor microenvironment; howev...Continue Reading

References

Jun 2, 1998·Molecular and Cellular Endocrinology·Y J Lee, J Gorski
Oct 1, 1998·The New England Journal of Medicine·G N Hortobagyi
Feb 17, 2001·Biochemical and Biophysical Research Communications·S SajiS Hayashi
Oct 26, 2001·Japanese Journal of Cancer Research : Gann·J KurebayashiH Sonoo
Aug 18, 2004·Biochemical Pharmacology·Maofu FuRichard G Pestell
Dec 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John Patrick AlaoDavid M Vigushin
Jun 27, 2006·The Journal of Steroid Biochemistry and Molecular Biology·Jungyoon ChoYoung Joo Lee
Sep 7, 2006·Endocrine-related Cancer·Anthony Howell
Sep 7, 2006·Endocrine-related Cancer·K S Kimbro, J W Simons
Mar 30, 2007·Proceedings of the National Academy of Sciences of the United States of America·Catherine M EakinRachel E Klevit
Jan 25, 2011·Clinical Epigenetics·Julia M WagnerManfred Jung
Apr 5, 2011·Biochemical and Biophysical Research Communications·Kwanghee RyuYoungjoo Lee
Feb 1, 2012·Molecular Carcinogenesis·Guang YanSusan Lanza-Jacoby
Jan 3, 2014·The Journal of Clinical Investigation·Alison C West, Ricky W Johnstone
Aug 28, 2014·International Journal of Cancer. Journal International Du Cancer·Deependra SinghAhti Anttila
Dec 3, 2014·Proceedings of the National Academy of Sciences of the United States of America·Debangshu SamantaGregg L Semenza
Aug 1, 2015·Proceedings of the National Academy of Sciences of the United States of America·Haiquan LuGregg L Semenza
Oct 6, 2015·Biochemical and Biophysical Research Communications·Junbiao Liu, Yan Li
Nov 26, 2015·International Journal of Cancer. Journal International Du Cancer·Sarah NechutaXiao Ou Shu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.